Chinese language Sinovac Biotech, with which the Well being Ministry of Ukraine signed an settlement on the acquisition of vaccines towards coronavirus (COVID-19) on the expense of the nationwide finances, licensed the Lekhim group of pharmaceutical corporations (Kyiv) to signify the pursuits of Sinovac Biotech in Ukraine for a interval of 5 years, ranging from November 25, 2020 till November 25, 2025.
This follows from a letter from Sinovac Biotech to the Well being Ministry and state-owned enterprise (SOE) Medical Procurement of Ukraine, the textual content of which is accessible to Interfax-Ukraine, despatched to the departments on the eve of the signing of the contract for the acquisition of the vaccine.
Because the Well being Ministry instructed Interfax-Ukraine, the division began direct communication with Sinovac Biotech in the summertime of 2020, it was concerning the provide of vaccines towards COVID-19 to Ukraine.
“By this time, the vaccine for the prevention of SARS CoV-2 an infection, developed by Sinovac Biotech, handed the second stage of scientific trials. Subsequently, Sinovac Biotech Ltd despatched a letter to the Well being Ministry and SOE Medical Procurement of Ukraine, which is the direct executor of the contractual circumstances, a letter stating that that Lekhim is the official licensed consultant of Sinovac Biotech. Throughout additional communication with Sinovac Biotech Ltd by way of numerous communication channels, representatives of Lekhim have been current, the Well being Ministry mentioned.
“Thus, the Sinovac Biotech Ltd Chinese language producer of vaccines towards SARS-CoV-2 has recognized Lekhim because the official consultant in Ukraine,” the division mentioned.
As reported, the Ministry of Well being by way of SOE Medical Procurement of Ukraine signed a contract for the availability of a vaccine produced by the Sinovac Biotech Chinese language firm to the nation as quickly as doable. In accordance with the contract, the price of the vaccine produced by Sinovac is UAH 504 per dose.